Combined use of ruxolitinib and sirolimus: increased monitoring of triglycerides required

被引：5

作者：

Bauters, Tiene ^{[1
]}

Bordon, Victoria ^{[1
]}

Laureys, Genevieve ^{[1
]}

Dhooge, Catharina ^{[1
]}

机构：

[1] Ghent Univ Hosp, Dept Pediat Hematol Oncol & Hematopoiet Stem Cell, C Heymanslaan 10, B-9000 Ghent, Belgium

来源：

BONE MARROW TRANSPLANTATION | 2019年 / 54卷 / 08期

关键词：

D O I：

10.1038/s41409-019-0488-2

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

引用

页码：1372 / 1373

页数：2

共 4 条

[1] New and emerging therapies for acute and chronic graft versus host disease [J].

Hill, LaQuisa ;

Alousi, Amin ;

Kebriaei, Partow ;

Mehta, Rohtesh ;

Rezvani, Katayoun ;

Shpall, Elizabeth .

THERAPEUTIC ADVANCES IN HEMATOLOGY, 2018, 9 (01) :21-46

[2] Emerging Therapeutics for the Control of Chronic Graft-versus-Host Disease [J].

MacDonald, Kelli P. A. ;

Betts, Brian C. ;

Couriel, Daniel .

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (01) :19-26

[3]

Watson A.P., 2018, CASE REP TRANSPLANT, V2018, P4539757, DOI [10.1155/2018/4539757, DOI 10.1155/2018/4539757]

[4] Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey [J].

Zeiser, R. ;

Burchert, A. ;

Lengerke, C. ;

Verbeek, M. ;

Maas-Bauer, K. ;

Metzelder, S. K. ;

Spoerl, S. ;

Ditschkowski, M. ;

Ecsedi, M. ;

Sockel, K. ;

Ayuk, F. ;

Ajib, S. ;

de Fontbrune, F. S. ;

Na, I-K ;

Penter, L. ;

Holtick, U. ;

Wolf, D. ;

Schuler, E. ;

Meyer, E. ;

Apostolova, P. ;

Bertz, H. ;

Marks, R. ;

Luebbert, M. ;

Waesch, R. ;

Scheid, C. ;

Stoelzel, F. ;

Ordemann, R. ;

Bug, G. ;

Kobbe, G. ;

Negrin, R. ;

Brune, M. ;

Spyridonidis, A. ;

Schmitt-Graeff, A. ;

van der Velden, W. ;

Huls, G. ;

Mielke, S. ;

Grigoleit, G. U. ;

Kuball, J. ;

Flynn, R. ;

Ihorst, G. ;

Du, J. ;

Blazar, B. R. ;

Arnold, R. ;

Kroeger, N. ;

Passweg, J. ;

Halter, J. ;

Socie, G. ;

Beelen, D. ;

Peschel, C. ;

Neubauer, A. .

LEUKEMIA, 2015, 29 (10) :2062-2068

← 1 →